rkozyD eF nd riksD hF nd rudsonD tF nd vvlD FrF nd frresiD F nd riltonEtonesD hF nd heshuerD wF nd rrrisD iF nd u(hD vF nd rwngD iF nd fshirD F nd lterD wFgF nd uruseD F nd vn den ferghD F nd sllD sF nd ¡ enissonEfesnierD sF nd he eleD vF nd urnullD hF nd quglieriD wF nd hrnkD fF nd hoserD fF nd eegerD tF nd hreierD rF nd ql¤ serD hF nd igleD wF nd fileyD qF nd ltersD F nd vongmnD gF nd xorwoodD pF nd inerD tF nd wuntoniD pF nd rnnD wF nd oertsD wF nd findo'D vFeF nd frierleyD gF nd gooperD FqF nd gottrellD hFeF nd hviesD xFF nd qisonD eF nd qormnD qFF nd rmmnsD F nd tksonD eFF nd uhnD eF nd vneD F nd wgonvilleD tF nd wintgrtD wF nd elEwemrD eF nd xixonD tF nd nikerD tF nd rtonD wF nd ettyD F nd rieD gFtF nd kowizD F nd yD F nd hpirD eFrF nd winglerD F nd urnerD gF nd gnerD uFF nd wddisonD F nd hwD FtF nd truD F nd fushyD uF nd vohm¤ ullerD rF @PHIQA 9exyS gene nlysis in lrge ohort of ptients with notminopthy X on(rmtion of mle prevlene nd high ourrene of the ommon exon S gene muttionF9D rumn muttionFD QR @VAF ppF IIIIEIIIVF Further information on publisher's website: httpXGGdxFdoiForgGIHFIHHPGhumuFPPQRP Publisher's copyright statement: his is the epted version of the following rtileX rkozyD eFD riksD hFD rudsonD tFD vvlD F rFD frresiD FD riltonEtonesD hFD heshuerD wFD rrrisD iFD u(hD vFD rwngD iFD fshirD FD lterD wF gFD uruseD FD vn den ferghD FD sllD sFD ¡ enissonEfesnierD sFD he eleD vFD urnullD hFD quglieriD wFD hrnkD fFD hoserD fFD eegerD tFD hreierD rFD ql¤ serD hFD igleD wFD fileyD qFD ltersD FD vongmnD gFD xorwoodD pFD inerD tFD wuntoniD pFD rnnD wFD oertsD wFD findo'D vF eFD frierleyD gFD gooperD F qFD gottrellD hF eFD hviesD xF FD qisonD eFD qormnD qF FD rmmnsD FD tksonD eF FD uhnD eFD vneD FD wgonvilleD tFD wintgrtD wFD elEwemrD eFD xixonD tFD nikerD tFD rtonD wFD ettyD FD rieD gF tFD kowizD FD yD FD hpirD eF rFD winglerD FD urnerD gFD gnerD uF FD wddisonD FD hwD F tFD truD FD fushyD uF nd vohm¤ ullerD rF @PHIQAD exyS qene enlysis in vrge gohort of tients with enotminopthyX gon(rmtion of wle revlene nd righ yurrene of the gommon ixon S qene wuttionF rumn wuttionD QR @VAX IIIIEIIIVD whih hs een pulished in (nl form t httpXGGdxFdoiForgGIHFIHHPGhumuFPPQRPF his rtile my e used for nonEommeril purposes in ordne ith iley erms nd gonditions for selfErhivingF Additional information:
rkozyD eF nd riksD hF nd rudsonD tF nd vvlD FrF nd frresiD F nd riltonEtonesD hF nd heshuerD wF nd rrrisD iF nd u(hD vF nd rwngD iF nd fshirD F nd lterD wFgF nd uruseD F nd vn den ferghD F nd sllD sF nd ¡ enissonEfesnierD sF nd he eleD vF nd urnullD hF nd quglieriD wF nd hrnkD fF nd hoserD fF nd eegerD tF nd hreierD rF nd ql¤ serD hF nd igleD wF nd fileyD qF nd ltersD F nd vongmnD gF nd xorwoodD pF nd inerD tF nd wuntoniD pF nd rnnD wF nd oertsD wF nd findo'D vFeF nd frierleyD gF nd gooperD FqF nd gottrellD hFeF nd hviesD xFF nd qisonD eF nd qormnD qFF nd rmmnsD F nd tksonD eFF nd uhnD eF nd vneD F nd wgonvilleD tF nd wintgrtD wF nd elEwemrD eF nd xixonD tF nd nikerD tF nd rtonD wF nd ettyD F nd rieD gFtF nd kowizD F nd yD F nd hpirD eFrF nd winglerD F nd urnerD gF nd gnerD uFF nd wddisonD F nd hwD FtF nd truD F nd fushyD uF nd vohm¤ ullerD rF @PHIQA 9exyS gene nlysis in lrge ohort of ptients with notminopthy X on(rmtion of mle prevlene nd high ourrene of the ommon exon S gene muttionF9D rumn muttionFD QR @VAF ppF IIIIEIIIVF Further information on publisher's website: httpXGGdxFdoiForgGIHFIHHPGhumuFPPQRP Publisher's copyright statement: his is the epted version of the following rtileX rkozyD eFD riksD hFD rudsonD tFD vvlD F rFD frresiD FD riltonEtonesD hFD heshuerD wFD rrrisD iFD u(hD vFD rwngD iFD fshirD FD lterD wF gFD uruseD FD vn den ferghD FD sllD sFD ¡ enissonEfesnierD sFD he eleD vFD urnullD hFD quglieriD wFD hrnkD fFD hoserD fFD eegerD tFD hreierD rFD ql¤ serD hFD igleD wFD fileyD qFD ltersD FD vongmnD gFD xorwoodD pFD inerD tFD wuntoniD pFD rnnD wFD oertsD wFD findo'D vF eFD frierleyD gFD gooperD F qFD gottrellD hF eFD hviesD xF FD qisonD eFD qormnD qF FD rmmnsD FD tksonD eF FD uhnD eFD vneD FD wgonvilleD tFD wintgrtD wFD elEwemrD eFD xixonD tFD nikerD tFD rtonD wFD ettyD FD rieD gF tFD kowizD FD yD FD hpirD eF rFD winglerD FD urnerD gFD gnerD uF FD wddisonD FD hwD F tFD truD FD fushyD uF nd vohm¤ ullerD rF @PHIQAD exyS qene enlysis in vrge gohort of tients with enotminopthyX gon(rmtion of wle revlene nd righ yurrene of the gommon ixon S qene wuttionF rumn wuttionD QR @VAX IIIIEIIIVD whih hs een pulished in (nl form t httpXGGdxFdoiForgGIHFIHHPGhumuFPPQRPF his rtile my e used for nonEommeril purposes in ordne ith iley erms nd gonditions for selfErhivingF Additional information: Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that:
• a full bibliographic reference is made to the original source • a link is made to the metadata record in DRO • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details. 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Identification of cases with isolated hyperCKaemia and very late symptomatic male and female subjects further confirms the broadensextension of the phenotypic spectrum of the disease. Anoctaminopathy appears to be one of the most common adult muscular dystrophies in Northern Europe, with a prevalence of about 20-25% in unselected undiagnosed cases. (Hicks et al, 2011) . LGMD2L, together with a more distal variant also known as non-dysferlin Miyoshi muscular dystrophy type 3 (MMD3) as well as some cases of isolated hyperCKaemia and pseudometabolic myopathy, have been shown to be associated with recessive mutations in the ANO5 gene (OMIM accession number 608662; Bolduc et al, 2010; Hicks et al, 2011; Milone et al, 2012; Deschauer et al, 2012; Schessl et al, 2012; Penttilä et al, 2012; Bouquet et al, 2012; Magri et al, 2012; Pénisson-Besnier et al, 2012; Wahbi et al, 2012; Witting et al, 2012; Little et al, 20132; Neusch et al, 2012 (Hicks et al, 2011) , and another in exon 20 (c.2272C>T) more frequent in the Finnish population (Penttilä et al, 2012) . Early clinical and MRI studies indicated wide clinical heterogeneity and a gender difference in expression, with anoctaminopathies appearing to be less frequent and less severe in females .
In the present study, we investigated the prevalence and spectrum of ANO5 gene mutations in the so far largest and clinically most heterogeneous cohort of 
Materials and Methods
The study was performed on a total of 205 unrelated individuals of both sexes, referred for ANO5 gene analysis to the Newcastle upon Tyne Limb-Girdle Referral
Centre in view of their phenotypes compatible with anoctaminopathy, ranging from isolated hyperCKaemia, myalgia and raised CK, to MMD3 and LGMD2L. Patients were referred from different clinical centers, but primarily from the UK, Germany, France, Spain, the USA and Belgium. The cohort previously reported by Hicks et al.
was not included in this study (Hicks et al, 2011 DNA extraction and direct sequencing of the ANO5 gene (Gene Bank accession number NM_213599.2) was performed as described elsewhere (Hicks et al, 2011) . Sequence variants were coded reflecting cDNA numbering with +1
corresponding to the A of the ATG translation initiation codon in the reference sequence, according to guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. Novelty of each sequence variant was checked in the ANO5 locus specific database (www.lovd.nl/ANO5). To investigate whether novel missense, synonymous or intronic variations not located in splice sites could possibly represent pathogenic 
Results

Genetic analysis
ANO5 gene sequence variants were identified in 90/205 unrelated individuals (46%) and 5 affected relatives (Table 1 , Suppl. Table 1) . Fifty-one patients were found to carry 2 or more ANO5 variants in homozygosity or compound heterozygosity, while further 39 patients showed one single ANO5 change (Tables 1   and 2 ). A total of 42 ANO5 gene variants were identified, 32 27 of which novel (Tables 1 and 2 ). Twenty variants were missense (47%), 4 frameshift (9%), 6 splice site (14%), 2 stop (5%), 1 synonymous (2%) and 10 intronic (24%) ( Table 2) (Tables 1 and 2 ). The common c.191dupA exon 5 mutation was found in homozygosity in 16 patients, in compound heterozygosity with another identified mutation in 19, and in heterozygosity without a 2 nd detectable mutation in further 5 individuals. Geographic origin of patients, indicated in Table 1 , confirms that the common variant is present also in populations other than the British and German populations. Additionally, two already reported (c. 692G>T, c.1927dupA ) and 2 novel (c.1898+1G>A, c.2417A>G) mutations were also identified in multiple patients, and further 3 novel changes were found in homozygosity in 3 individuals (Tables 1 and 2 ). Parental DNA screening or ANO5 genomic dosage analysis was not performed yet for the homozygous patients, and hemizygosity of parts or the entire ANO5 locus cannot be ruled out.
Phenotypic analysis
Among patients with 2 likely pathogenic changes (total 47 patients, including 42 unrelated subjects and 5 affected relatives), 39 were male (83%) and 8 were female (17%). Clinical information was available for 4144 patients and relatives with 2 pathogenic changes 44 patients (34 males, and 7 females) ( 
Discussion
In this study we report on the clinical analysis and molecular screening of the ANO5 gene in the largest cohort of anoctaminopathy patients identified so far. Our results confirm the high frequency of the common c.191dupA mutation which represents 51/84 (61%) of mutated alleles in the cohort of patients with two mutations (Tables 1 and 2 ). Occurrence of this Northern European founder mutation in patients of different geographic origin indicates that it has likely spread worldwide, although at lower frequencies compared to the British and German populations. This is corroborated by the observation that the mutation has not been observed in homozygosity in other populations, with the exception of two unrelated French patients (Wahbi et al, 2012) . However, our result could have been biased by the predominance of British and German patients in our cohort. (Tables 1 and 2 ). Mutations are spread across the gene, indicating the absence of additional mutation hot spots, although some mutations appear to be recurrent (Tables 1 and 2 ). The frequency of the second most common variant (c.692G>T) suggests that it could represent an additional common change in our population (Table 1) . Interestingly, the common Finnish mutation appears to be rare in our cohort, with a single occurrence in a German patient in compound heterozygosity with the c.191dupA mutation (Pt N.35). Mutations leading to loss of protein function (frameshift, splice and stop mutations) were the most common changes in the "2-mutation" group of patients (66/84 alleles, 79%) although the relative frequency of missense changes (18/84 alleles, 21%) could imply further pathogenetic mechanisms.
We have identified several exonic changes that appear to be benign variants or to have uncertain pathogenicity. Among these, the non pathogenic variant c.155A>G
(p.Asn52Ser) in exon 4 (dbSNP rs143777403), found with allelic frequency of 0.0001-0.001 in North American and African American control populations, was identified in 5 patients from our cohort. The c.2387C>T (p.Ser796Leu) in exon 22, also a benign variant by in silico analysis, was found in another individual.
Interestingly, these two missense variants were described as pathogenic by Wahbi and coauthors (2012) in 3 unrelated subjects, one of which was compound heterozygous for this and the c.155A>G variant. These findings point towards caution when novel missense changes are found (especially if in compound heterozygosity), and no further data corroborating the pathogenicity of the change is available. We identified 3 patients who were homozygous for a novel variant and 14 patients with 1 heterozygous change only. One of the limitations of this study is the lack of cDNA deletion/duplication analysis is currently in progress in some of these individuals.
We have previously described the clinical phenotype of anoctaminopathies as an adult onset disease, characterized by slowly progressive muscle weakness mainly affecting the pelvic girdle and the lower limbs (Hicks et al, 2011) . Clinical analysis of the present cohort of patients extends our initial findings to a large group of patients not restricted to the common founder mutation (Table 3 ). Being our center the only currently offering ANO5 screening in the UK, the prevalence of proximal disease is unlikely to be caused by the referral bias previously suggested (Hicks et al, 2011) . No major significant cardiac or respiratory disease was observed in this cohort, suggesting that these are not major features of the condition. We provide further evidence for male predominance in anoctaminopathies, females being overall less frequently and less severely affected than males (Hicks et al, 2011 , Penttilä et al, 2012 . Phenotypic analysis of the here reported affected females reveals a milder clinical picture, with 5 patients showing only raised CK values or calf hypertrophy.
The oldest female individual, homozygous for the common exon 5 mutation, showed a late disease onset (64 years), and at the age of 68 years she was still ambulant and she was able to stand on tiptoes and heels with minor difficulties. These findings suggest that gender differences could be in part due to the milder phenotype of affected females that is therefore less likely to be ascertained. In fact, two asymptomatic females were identified after a molecular diagnosis was reached in their brothers. Recruitment bias could also be in part be responsible for gender difference, as patients seen in specialized centers usually show a more severe phenotype, and therefore females with milder phenotypes might not come as frequently to our attention. In this study, we also identified 4 male subjects showing a very mild (Table 3 ). In particular, one subject only showed symptoms in his late 70s, confirming that indeed age at onset and severity of anoctaminopathies can be extremely variable also in males (Hicks et al, 2010; Schessl et al, 2012; Penttilä et al, 2012) .
No genotype-phenotype correlations were noted in anoctaminopathy so far.
Nevertheless, a clinical comparison between patients carrying the common exon 5 mutation and those carrying different changes revealed some interesting findings ( While we cannot exclude a second non-yet identified change in these subjects, family analysis of one individual (Pt. N.50) showed that raised CK values segregated with the heterozygous mutation in 2 other family members (data not shown). An association between isolated hyperCKaemia and ANO5 heterozygous carrier status was suggested by Milone and coworkers, who identified an otherwise asymptomatic carrier of the c.191dupA mutation (Milone et al, 2011) . Likewise, isolated hyperCKaemia or very mild phenotypes were also found in a few male and female patients carrying two pathogenic ANO5 mutations (Hicks et al, 2011; Schessl et al, 2012; Penttilä et al, 2012 , Wahbi et al, 2012 . Systematic analysis of ANO5 gene in wider cohort of subjects with isolated hyperCKaemia, as well as CK measurements in otherwise healthy heterozygous family members could help to clarify these findings.
Our results show that ANO5 gene mutations are responsible for about ¼ of cases of undiagnosed muscular dystrophy with adult onset and raised CK, screened at our service over the last two years (present series and Hicks et al, 2011) . This value is similar to what reported in the Finnish population (Penttilä et al, 2012) and indicates anoctaminopathy as one of the most common form of LGMD in our population, possible reflection of the founder effects observed in Northern Europe (Hicks et al, 2011) . Indeed, observed incidences in the UK and Finland are higher than in Italy (Magri et al, 2012) where only about 2% of undiagnosed LGMD patients were shown to carry ANO5 mutations. Based on its relative frequency, screening of the ANO5 gene now represents an early step in the diagnostic work-up of these patients.
However, in view of the increasing genetic heterogeneity and prevalence of families without the common mutation (14%), analysis should not be limited to founder mutations only (Penttilä et al, 2012) . More systematic studies on isolated hyperCKaemia patients will also help in giving better prevalence data for anoctaminopathies in general.
In conclusion, we confirmed that ANO5 gene mutations are responsible for about ¼ of cases of undiagnosed muscular dystrophy in our population, being the exon 5 change the most prevalent. We expanded the allelic heterogeneity of the disease and recognized a broader clinical spectrum of the disease, ranging from isolated hyperCKaemia to full blown LGMD2L, with clear male predominance both in terms of overall prevalence and severity of the disease.
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